Joint contract with the pharmaceutical company Eli Lilly for the supply of treatment monoclonal antibodies for patients with coronavirus, signed by the European Commission.
The contract was signed in the framework of its Strategy The European Union for therapies against Covid-19 which, as the Commission announced last June, will include a portfolio of five promising remedies against the disease.
The specific treatment of Eli Lilly is found under rolling evaluation of the European Medicines Agency (EMA), according to the RES EPA response from Brussels. In total, 18 Member States signed the joint contract for the purchase of up to 220.000 monoclonal antibody therapy.
The Commissioner for Health and Food Safety Stella Kyriakidou said: “Above 73% of the EU adult population is now fully vaccinated and this percentage will continue to rise. But vaccines may not be our only answer to COVID-19. People are still infected and sick.
We must continue our work to prevent the disease with vaccines and at the same time ensure that we can treat it with therapeutic agents. With today’s contract, we complete our third supply and implement our commitment based on the EU Therapeutic Strategy. to facilitate access to state-of-the-art drugs for patients with COVID-19 “.
The Commission in its communication emphasizes that “while vaccination remains the strongest advantage against the virus and its variants, treatments play a critical role in the treatment of COVID-19. “They help save lives, speed up recovery time, reduce the length of hospital stay and ultimately reduce the burden on health systems.”
Eli Lilly’s product is a combination of two monoclonal antibodies (bamlanivimab and etesevimab) for the treatment of patients with coronavirus who do not need oxygen but are at high risk of serious disease from COVID-19, broadcasts APE BPE.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight the coronavirus. They bind to the peak protein and thus inhibit it virus attachment in human cells.
Under the EU’s joint procurement agreement, the Commission has so far concluded almost 200 contracts for various medical countermeasures with a cumulative value of more than EUR 12 billion.
Under the joint procurement contract concluded with Eli Lilly, Member States may purchase the combined product bamlanivimab and etesevimab if and when necessary, after receiving either marketing authorization conditionally at European Union level by the European Medicines Agency, either emergency license emergency in the Member State concerned.
* File photo
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
